Most patients with coronary artery disease (CAD) and chronic stable angina will obtain complete relief of symptoms with percutaneous coronary intervention (PCI). However, some chronic angina patients ...
New Orleans, La. (March 27, 2007) — Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new ...
Did this woman’s additional bouts of pain warrant emergent repeat of previously negative angiography? Ms. P, a 54-year-old African American with a known history of hypertension, diabetes mellitus, and ...
Ranolazine is an antianginal drug and a class V antiarrhythmic drug that is mainly used for the treatment of chronic angina. Ranolazine is also used off-label to treat certain arrhythmias, including ...
Background: Chronic angina carries an economicburden because of symptom management, the riskof major cardiovascular events, and lost productivity.The level of these costs has not been ...
Please provide your email address to receive an email when new articles are posted on . The first-ever guidance on recurrent, low-risk chest pain provides a good starting point for addressing a ...
Trimetazidine on top of standard therapy among patients who’ve undergone PCI for stable angina or NSTE ACS doesn’t affect their long-term outcomes, the ATPCI trial has shown. Participants in the ...
In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results